Emmanuel Mitry
Emmanuel Mitry is an expert in Oncology at Institut Paoli-Calmettes (France). As of September 2026, ScienceLeadR ranks Emmanuel Mitry in the top 1% of experts worldwide for Intestinal Neoplasms and Carcinoma. Emmanuel Mitry has authored 329 publications, the most recent in 2026, and is an investigator in 24 clinical trials, 10 of them ongoing. SLR score: 1,178 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Gastroenterology - Surgery - Hepatology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1997 - 2026
Number : 329
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer. PMID 42507965 — intelligence, pancreatic neoplasms, neoplasms, drug therapy, biomarkers, chemotherapy, adjuvant, deep learning, histology, therapeutics, medical oncology, learning, artificial intelligence, chemotherapy | J Clin Oncol Top journal | 2026 | 2 |
| Circulating tumor DNA dynamics and clinical outcomes in patients with advanced Colorectal Cancer treated with cetuximab-based induction and maintenance treatment. PMID 41671078 — circulating tumor dna, cetuximab, induction chemotherapy, neoplasms, disease progression, drug therapy, maintenance, therapeutics, colorectal neoplasms, random allocation, dna, chemotherapy | Clin Cancer Res | 2026 | 0 |
| Factors Associated With Toxicity of FOLFIRINOX in Elderly Patients With Pancreatic Ductal Adenocarcinoma. PMID 41397201 — neoplasms, adenocarcinoma, aged | JCO Oncol Pract | 2025 | 0 |
| CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1. PMID 41061701 — cells, pancreatic neoplasms, biological science disciplines, neoplasms, drug therapy, biomarkers, immunotherapy, tumor microenvironment, chemotherapy | Cell Rep Med | 2025 | 0 |
| Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study. PMID 40829093 — quality of life, safety, esophagogastric junction, neoplasms, drug therapy, therapeutics, medical oncology, chemotherapy | J Clin Oncol Top journal | 2025 | 0 |
Clinical Studies 24
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
10 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX versus mFOLFIRINOX Alone in Patients with Resected Pancreatic Ductal Adenocarcinoma 2022-502404-73-00 — safety, adenocarcinoma | Phase 2 | Recruiting | 2024 |
| DOVIPA a phase II study evaluating efficacy and safety of DOstarlimab and oral VItamin D3 with folinic acid 5FU Irinotecan plus oxalipaltin (mFOLFIRINOX) in non pretreated metastatic PAncreatic Cancer 2023-510004-49-00 — leucovorin, pancreatic neoplasms, safety, vitamins, neoplasms, fluorouracil, irinotecan, cholecalciferol | Phase 2 | Active not recruiting | 2025 |
| TAR 0520 gel in EGFR inhibitor induced folliculitis 2024-516339-28-00 — folliculitis | Phase 2 | Not yet recruiting | 2025 |
| A Study to Assess the Adverse Events and Change in Disease Activity of Multiple Treatment Combinations with Telisotuzumab Adizutecan in Participants with Metastatic Colorectal Cancer 2024-512981-33-00 — safety, neoplasms, drug-related side effects and adverse reactions, therapeutics, colorectal neoplasms | Phase 2 | Recruiting | 2025 |
| TAR 0520 Gel in Hand and Foot Syndrome NCT07457671 — hand-foot syndrome, neoplasms, foot, therapeutics, capecitabine | Phase 2 | Not yet recruiting | 2026 |
LeadR Networks
Main global connection map